Cardiovascular disease (CVD) mortality increased by 78%, rising from 72.4 to 128.7 per 100 000 (2017–2022), with the greatest ...

The increasing demand for donor hearts presents both a critical challenge and a significant opportunity for innovation in ...

Several in-hospital therapies that have historically been used to treat patients with ICH appear to confer either no benefit or harm. For emergency or critical care treatment of ICH, prophylactic ...

Hypertriglyceridemia (triglycerides 200–499 mg/dL) is relatively common in the United States, whereas more severe triglyceride elevations (very high triglycerides, ≥500 mg/dL) are far less frequently ...

Clinical data standards aim to identify, define, and standardize data elements relevant to clinical topics in cardiovascular medicine, with the primary goal of assisting data collection and use by ...

Circulation: Arrhythmia and Electrophysiology A specialized journal dedicated to advancing the understanding and management of cardiac arrhythmias and electrophysiology Editor-in-Chief: Paul J. Wang, ...

BACKGROUND: Evaluation of whether dyspnea has a cardiac cause is essential. Guidelines from 2016 were reported to result in a ...

The expression and function of NPRC in DKD were investigated using human renal biopsies and a diabetic mouse model. Podocyte-specific NPRC knockout mice were developed to explore the role of NPRC in ...

Cardiovascular disease (CVD) is the predominant cause of death globally, accounting for ≈30% of deaths each year. 1 The prevalence of CVD among adults (aged ≥20 years) in the United States was 48.6% ...

CD34-lineage cells were found to be the major source of cells differentiating into T cell populations in allograft arteries. CD34-lineage cells mainly originated from the thymus, with drainage through ...

Despite an overall population‐wide decline in cardiovascular disease (CVD) mortality in the United States since 1968, 1 detailed analysis of age‐specific rates reveals concerning trends within young ...

BACKGROUND: Clinical guidelines recommend different revascularization strategies for nonculprit lesions in patients with ST-segment–elevation myocardial infarction (STEMI) versus non-STEMI (NSTEMI).